$LLY · Eli Lilly and Company

Eli Lilly and Company filed a Form 3 with the SEC on October 22, 2026, reporting an initial ownership position in Lycia Therapeutics, Inc. (LYCA). The filing states that Eli Lilly directly beneficially owns 1,104,558 shares of Lycia common stock. A footnote explains that these shares are expected to be issued upon the mandatory conversion of convertible preferred stock in Lycia’s initial public offering, and they do not include any common stock purchased in that offering because the amount was not known at the time of filing.

The filing identifies Eli Lilly as a 10 percent owner of Lycia. In the remarks section, Eli Lilly states that after the closing of Lycia’s initial public offering, including its purchase in the offering, it will cease to be a 10 percent owner. As a result, Eli Lilly will have no further Section 16 reporting obligations with respect to Lycia. The Form 3 was signed by Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary.